Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
says Dec. 7, 2006
sounds great so far
NEW - online interview with GRSR
check it out. just scroll down half way on page until you see that audio player button...dated today
- http://www.ludlowcapital.com/reports/grsr.htm
welcome weo...
hope to have you on board soon, think this is getting tight and gonna pop either way up or down. Im betting up and a pro-AE congress this Jan.
CBPC - bird flu & Influenza play
BIRD FLU TESTING (has copy of deadly H5N1 virus)
Avian (“Bird Flu”) H5N1 Virus – By February 2004, the avian or “bird” flu spread across 10 countries in Asia and caused dozens of deaths in Thailand and Vietnam. In China, the bird flu affected more than half of all provinces and territories. CBPC stands to be a major player in creating and mass-producing a vaccine for a potential pandemic bird flu outbreak. In June 2006, China Biopharma received a copy of the H5N1 virus (a deadly virus transmitted from bird to human), and has begun animal testing on a vaccine.
http://chinabiopharma.net/index_4.asp
INVESTMENT HIGHLIGHTS
- Market Growth – the market in China for flu vaccinations has grown from 3.9 million doses in 2000 to 22.3 million doses in 2005, or 30% year over year.
- Distribution Network – the company has the largest independent vaccine distribution network covering 268 cities in China.
- Strategic Alliances – the company retains a close relationship with the Chinese Center of Disease Control (CDC), providing local CDC vaccinations, and providing their high-capacity production facility for any potential epidemics within China.
- Product Pipeline – in addition to marketing vaccines for Influenza, Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the company is also conducting research such new products to cover allergies and avian bird flu.
- Revenue Projection – management anticipates generating $10 million in annual revenues and positive net income for fiscal year 2006.
- Management Experience – the company retains some of the top scientists within the human vaccine fields in China, and has had a number of years experience running a public company
CBPC - Bird Flu Vaccine
Avian (“Bird Flu”) H5N1 Virus – By February 2004, the avian or “bird” flu spread across 10 countries in Asia and caused dozens of deaths in Thailand and Vietnam. In China, the bird flu affected more than half of all provinces and territories. CBPC stands to be a major player in creating and mass-producing a vaccine for a potential pandemic bird flu outbreak. In June 2006, China Biopharma received a copy of the H5N1 virus (a deadly virus transmitted from bird to human), and has begun animal testing on a vaccine.
http://chinabiopharma.net/index_4.asp
Key points on CBPC - big!!!
INVESTMENT HIGHLIGHTS
- Market Growth – the market in China for flu vaccinations has grown from 3.9 million doses in 2000 to 22.3 million doses in 2005, or 30% year over year.
- Distribution Network – the company has the largest independent vaccine distribution network covering 268 cities in China.
- Strategic Alliances – the company retains a close relationship with the Chinese Center of Disease Control (CDC), providing local CDC vaccinations, and providing their high-capacity production facility for any potential epidemics within China.
- Product Pipeline – in addition to marketing vaccines for Influenza, Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the company is also conducting research such new products to cover allergies and avian bird flu.
- Revenue Projection – management anticipates generating $10 million in annual revenues and positive net income for fiscal year 2006.
- Management Experience – the company retains some of the top scientists within the human vaccine fields in China, and has had a number of years experience running a public company
got this from their fact sheet.....this is big!
link - http://www.theasianinvestor.com/reports/cbpc.htm
Boxer promises change on global warming
Boxer promises action on global warming laws
She will lead environment committee
By JOHN HEILPRIN
Associated Press
WASHINGTON - The Democrat poised to take over the Senate environment committee promises a ''sea change'' from six years of Republican inaction on global warming and says she expects Congress to send President Bush legislation to start curbing greenhouse gases.
Sen. Barbara Boxer of California, who will lead the Environment and Public Works Committee beginning in January, acknowledged Tuesday she may fall short of her goal: imposing the nation's first mandatory limits on industrial emissions of carbon dioxide and other heat-trapping gases.
''I have no line in the sand,'' she said in an interview with The Associated Press. ''Even a little step will look like a big step.''
In the interview, Boxer also promised to end Bush administration rollbacks on environmental rules if they are not supported by science.
''Any kind of weakening of environmental laws or secrecy or changes in the dead of night -- it's over,'' Boxer said. ''We're going to for once, finally, make this committee an environment committee, not an anti-environment committee.... This is a sea change that is coming to this committee.''
http://www.montereyherald.com/mld/montereyherald/news/state/16174995.htm?source=rss&channel=mont...
FMII - .005 x .0055 (+ 57% - gay travel play)
FMII moving up.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=fmii&sid=0&o_symb=fmii&f...
this a joke?
brought it right back below the 200 day moving average. Sheesh! Come on with the selling into every rally. Let this thing go already.
GRSR.pk - applies for OTC listing
GRSR has filed their form 15c2-11, and is currently fully reporting with $51.9 million in revenue for the 9 months.
Application is in with OTC and could get approval to begin trading at any moment.
GRSR - .63 x .68
- trading below 1 times sales
- sector average is 10 times sales
- only 34 million outstanding
- revenues = $51.9 million
OT: FMII - gay travel sites
Franchise Management International Announces Additional Licenses, Trademarks, and Assets Involved in Pending Netadventures, Inc. Acquisition
BRICK, NJ, Dec 05, 2006 (MARKET WIRE via COMTEX) -- Franchise Management International, Inc. (PINKSHEETS: FMII), a premier provider of public charter and transportation services, today announced additional licenses and trademarks acquired in its binding pending letter of intent with Netadventures, Inc.
In addition to the GayTravel.Com web property, which saw over 26,000,000 hits from statistics available between 2003-2004, Franchise Management International has also negotiated the rights and domain registrations to the following additional sites:
www.gaytravel.net
www.gay-travel.com
www.gay.travel
www.gay-travel.net
www.1-800-gay-travel.com
www.800-gaytravel.com
www.gaivoyage.com
www.gaycorsa.com
www.gaytraveler.com
www.gaycurso.com
www.netadventuresinc.com
If the acquisition is consummated, Franchise Management would also control US Trademark Reg No. 2,034,655 for the mark 'Gay-Travel' ("the Licensed Mark") as well as the rights and operations of the following toll-free telephone numbers:
1-800-Gay-Travel
1-888-Gay-Travel
1-877-Gay-Travel
1-866-Gay-Travel
The company is extremely excited about the revenue possibilities these assets, licenses, and trademarks represent, and believe that utilizing them under its 2007 business plan will result in significant shareholder value.
big news - export division
Linkwell Corporation Launches Exporting Division Anticipating Additional Revenues of $5 Million and 10% Net Profit Margin From This New Division in 2007
SHANGHAI, CHINA, Dec 06, 2006 (MARKET WIRE via COMTEX) -- Linkwell Corporation (OTCBB: LWLL), a leading developer, manufacturer and distributor of healthcare-related disinfectants in China, today announced it has fully launched the operations of its exporting division, Shanghai LiKang International Trade Company, Limited, a wholly owned subsidiary of Linkwell.
LiKang International was established by Shanghai LiKang Disinfectant High-Tech Company, Limited with registered capital of $250,000. The main business of LiKang International covers but is not limited to various import and export activities. LiKang International, which began operations in July 2006, has mainly served as an agent for third parties who desire to import or export goods. Presently LiKang is expanding its scope of goods to include lightweight construction materials, textile crafts, furniture, and chemical raw materials.
The new division will be headed by Mr. Wei Guan, Vice President and Director of Linkwell Corporation. Mr. Guan has extensive experience in the import/export business. From 1987 to 1990, Mr. Guan worked in a management capacity for Hunan Machinery Importing and Exporting Corporation. From 1990 to 2002, Mr. Guan worked as general manager for a Division of Importing and Export at Worldbest Group in Shanghai. Mr. Guan graduated from Hunan University in Changsha, Hunan Province with a bachelor's degree in International Trading in 1987.
Mr. Xuelian Bian, CEO and President of Linkwell Corp., stated, "We are very excited about this new division. We will utilize our marketing savvy capabilities to extend to a new business sector in order for us to improve our financial performance and broaden our revenue base. We expect this division alone will generate over $5 million in annual revenues with approximately 10% net profit margin in the fiscal year of 2007."
About Linkwell Corporation
Linkwell Corporation (OTCBB: LWLL) develops, manufactures, and distributes disinfectant healthcare products in China through its 90% owned subsidiary Shanghai LiKang Disinfectant High Tech Company ("LiKang"). Linkwell's disinfectant healthcare products are a nationally recognized domestic Chinese brand in this market segment. Linkwell products include disinfectants in liquid, tablet, powder and aerosol form. Through LiKang, Linkwell has a national marketing and sales presence throughout all 22 provinces, 5 autonomous regions, and 4 special municipalities of China. All inventory and order fulfillment is carried out of a 21,500-square-foot facility in Shanghai's Jiading district. For more info about the company, please visit http://www.linkwell.us
LWLL - launches export division
Mr. Xuelian Bian, CEO and President of Linkwell Corp., stated, "We are very excited about this new division. We will utilize our marketing savvy capabilities to extend to a new business sector in order for us to improve our financial performance and broaden our revenue base. We expect this division alone will generate over $5 million in annual revenues with approximately 10% net profit margin in the fiscal year of 2007."
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=lwll&sid=0&o_symb=lwll&f...
FMII - .004 x .0047 (gay travel)
Acquiring a gay travel company. Gay's consist of 10% of the total travel market in the US....BIGGGG!!!
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=fmii&sid=0&o_symb=fmii&f...
.41 x .43
may try to bounce off the 200 day which would be great. Interview was cool, and expecting much more news out of China on this one.
http://finance.yahoo.com/q/bc?s=CBPC.OB&t=5d
China BioPharma (CBPC) - $1.30 target
Influenza vaccines -
http://www.theasianinvestor.com/reports/cbpc.htm
APYM to acquire -> SMS Biz Sdn. Bhd.
The business alliance agreement calls for: (i) Asia Payments to become the primary distributor for SMSBIZ; and, (ii) the SMSBIZ Shareholders to grant Asia Payments a 3-year option to acquire 100% of their shareholdings in SMSBIZ for a consideration of 5 million restricted common shares issued by Asia Payments; and, conditional upon certain events and undertakings, an additional 2 million restricted common shares upon exercise of the option. The distribution of SMSBIZ products will have an immediate impact on Asia Payments' revenues and will also provide greater synergies arising within Asia Payments' payment processing systems.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=apym&sid=0&o_symb=apym&f...
CBPC -> China BioPharma
Take a look at China BioPharma (OTC:CBPC) - seems to be a real deal human vaccine company, with real Influenza vaccine.
RECENT NEWS
- China Biopharma and HYTE Research LLC Enter into Technology Partnership to Improve Safety and Efficacy of Human Vaccines
- China Biopharma to Present at BioPharm Asia 2006 in Singapore
- China Biopharma Delivers 1.5 Million Doses of Flu Vaccine in China
- Company Receives LOI to Deliver 450,000 Doses of Flu Vaccines to Local Social Security Healthcare Management Center
- China Biopharma Receives Order to Export Flu Vaccine to Macedonia
* Projecting $10 million in revenue.
TAKE A LOOK
http://finance.yahoo.com/q?s=CBPC.OB
FMII - .004 x .0045 (gay travel)
Gay's consist of 10% of the total travel market, big.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=fmii&sid=0&o_symb=fmii&f...
OT: GRSR - below 1 times sales
GiraSolar (OTC:GRSR) - undervalued solar play
- most solar stocks trade at 10 times sales
- GRSR is trading below 1 times sales
- posted $51.9 million in sales for 9 months ending Sept. 2006
- only 34 million outstading
- very close to profit (only few solar stocks are profitable)
- OTC listing approval anyday
- at just 5 times sales GRSR should be at $6.00 a share
Cold weather pushing Oil higher
Above $63 on cold weather and OPEC cut coming. Should provide additional interest in AE stocks.
Ludlow China SmallCap Index
http://www.ludlowcapital.com/indices/
GRSR to move into California....
That would be big!
In the USA we are active in strengthening our position and we are diligently working on acquisitions and partnerships in Arizona, New Mexico and California.
news
GiraSolar Enters New Markets Successfully; Estimated 12% Market Share in Spain
Monday December 4, 8:00 am ET
DEVENTER, THE NETHERLANDS--(MARKET WIRE)--Dec 4, 2006 -- GiraSolar, Inc. (Other OTC:GRSR.PK - News) (Frankfurt:L2I.F - News) is pleased to announce it has presented itself in a number of international solar exhibitions and conferences in emerging solar markets, and has increased its market share in Spain to 12%.
CBPC - breaks 200 day moving average (chart)
China BioPharma (OTC:CBPC) + 19% today
http://www.investorshub.com/boards/board.asp?board_id=6973
CEO's background - solid!
The guy worked for Chiron vaccines....that was a big company.
------
Jean-Denis SHU MD, MBA, CEO of China BioPharma (OTC:CBPC)
Highlights:
Witness and player of ten-year growth of the Chinese vaccine market with strong resources and network. Expertise in business start-ups and general management in Asia-Pacific region, and a proven rack-recorded successes in medical and marketing management in France and China. French citizen born in China, bi-cultural and tri-lingual (English, French and Chinese). Medical Specialist qualified in France plus an international MBA degree. President, Far East & North Pacific of Chiron Vaccines
Professional experiences:
Chiron Vaccines, Chiron, Beijing Representative Office, Beijing 100026, China
January 2003 – March 2006: President Far East & North Pacific
Major achievements:
- Built a regional representative office responsible for China, South Korea, Taiwan and Hong Kong
- Built and directed a team of 12 employees covering regulatory affairs, marketing promotion and commercial operations
- Increased regional turnover from 10 millions USD to 20 millions USD during two years, and could reach 30 millions USD in the third year if there was no supply shortage
- Transformed the products with the lowest price into the highest one on the regional markets
- Built business in China from zero: set up distributorship, launched two products and submitted three products for registration; able to brand the company and its products
- Developed a long-term strategy and country plan for China
Ludlow China Target = $1.30
Ludlow China Upgrades CBPC Rating to B, Maintains $1.30 Price Target
VALUATION PRICE TARGET OF $1.31
CBPC is projecting $10 million in sales for fiscal year 2006, and with only 84 million shares issued and outstanding we feel CBPC should have a fair market cap value of at least $110 million. This valuation is based on a price/sales ratio of 11, similar to Sinovac (SVA), which is the closest business model and sector of the above companies.
$10 million (revenue) x 11 (price to sales) = $110 million market cap
($110 million market cap / 84 million shares outstanding = $1.30 a share)
CBPC recent break through its 200 day moving average, projecting $10 million in vaccine sales, $1.5 million in net income, and sector price to sales ratio comparison of 11, has made CBPC an attractive biotech play within the Influenza sector. Based on this information, Ludlow China is upgrading CBPC rating to B, and maintaining its valuation target of $1.30 a share based on projected $10 million in vaccine sales.
* Ludlow China began coverage on China BioPharma (CBPC) on March 21, 2006 at a price of $0.50 a share. See disclaimer below.
http://www.theasianinvestor.com/reports/cbpc.htm
Nice. If you read that report you see that most other flu stocks traded at like 11 to 100 times sales. If CBPC is projecting $10 million in vaccine sales that means at just say 10 times sales CBPC should be trading with a market cap of $100 million market cap. With 84 million shares out....well, you do the math.
Market cap now is $42 million
CBPC biggest chinese % gainer
CBPC biggest % gainer in Chinese small cap area again today, sweet.
http://www.ludlowcapital.com/indices/china/historic/smallcap.html
.50
this looks like a true break out above the 200 day MA. We now are facing 'The Wall' at .51.....break .51 and we continue the run. Sweet!
EMKR invests $18 mill into WWAT
EMKR
http://finance.yahoo.com/q?s=EMKR
WWAT
http://finance.yahoo.com/q?s=wwat.ob
yes, they have big numbers
big earnings. Also a component of this China index. CHNG and CBPC are one of the biggest gainers of small cap Chinese stocks today, sweet.
http://www.ludlowcapital.com/indices/china/smallcap.html
short squeeze - real reversal
This is looking awsome. Real bids and .45 breaking down, and .50 next target. Looking for anyone who's still short to cover as it breaks .45 as a confirmation of real reversal. Awsome.
so close to breaking 50 day MA
http://stockcharts.com/h-sc/ui?s=GRSR&p=D&yr=0&mn=8&dy=0&id=p67989586030
CBPC - breaking 200 day MA
http://www.investorshub.com/boards/board.asp?board_id=6973
CBPC - breakin 200 day MA (chart)
http://www.investorshub.com/boards/board.asp?board_id=6973
looks like we may run for .50+ today
whoa, this really could be the break out.
DSTI, WWAT, & XSNX all running
what the fu,k GRSR.....geez
dont know about .75 tomorrow....
but the close above the 200 day was awsome. Now it has to break above .45 tomorrow and close above it for me to truely belive its reversed. Seen it break this before only to run down. But i dont know what it is....with level 2 and volume Im believing this may actually be the break.
Now, if we can get some flu outbreaks in the news this could find new eyes. Flu doesnt really kick in till Dec to March.
Close above 200 day looks awsome. If we get follow through buying in morning we may also see some short covering as well. hehe.
Chinese small cap index
http://www.ludlowcapital.com/indices/china/historic/smallcap.html
Intraday (CBPC biggest gainer)
http://www.ludlowcapital.com/indices/china/smallcap.html
Also large cap Chinese stocks
http://www.ludlowcapital.com/indices/china/historic/index.html
chart above (break above .45)
If we can see CBPC break above and close above .45 a share this would confirm this thing has broken out of its downtrend and will be moving up. Volume impressive, think this may actually be ready to go. Watching level 2 and the .41 to .43 mark for break of 200 day moving average.